---
figid: PMC3588168__nihms-317231-f0001
figlink: /pmc/articles/PMC3588168/figure/F1/
number: Figure 1
caption: Simplified schematic of signaling pathways driving resistance to BRAF inhibitors.
  In BRAF V600E mutant melanoma cells (left), BRAF inhibition causes growth arrest
  and apoptosis by blocking the MAPK pathway. These BRAF-inhibitor (BRAFi-) sensitive
  cells are highly dependent on BRAF for MAPK activation and survival. Following chronic
  BRAF inhibition, resistant cells (right) evolve an array of compensatory mechanisms,
  including RAF isoform switching, activation of RTKs such as IGF-1R, and engagement
  of the PI3K pathway to promote cell survival. PTEN loss leads to activation of the
  PI3K pathway. Understanding the signaling networks that drive drug resistance will
  enable the development of rational drug combinations to target melanomas refractory
  to BRAF inhibitors. Also shown are inhibitors that can be used to block the compensatory
  pathways identified so far.
pmcid: PMC3588168
papertitle: 'Resistance to BRAF inhibitors: Unraveling mechanisms and future treatment
  options.'
reftext: Jessie Villanueva, et al. Cancer Res. ;71(23):7137-7140.
pmc_ranked_result_index: '14447'
pathway_score: 0.9664574
filename: nihms-317231-f0001.jpg
figtitle: Simplified schematic of signaling pathways driving resistance to BRAF inhibitors
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3588168__nihms-317231-f0001.html
  '@type': Dataset
  description: Simplified schematic of signaling pathways driving resistance to BRAF
    inhibitors. In BRAF V600E mutant melanoma cells (left), BRAF inhibition causes
    growth arrest and apoptosis by blocking the MAPK pathway. These BRAF-inhibitor
    (BRAFi-) sensitive cells are highly dependent on BRAF for MAPK activation and
    survival. Following chronic BRAF inhibition, resistant cells (right) evolve an
    array of compensatory mechanisms, including RAF isoform switching, activation
    of RTKs such as IGF-1R, and engagement of the PI3K pathway to promote cell survival.
    PTEN loss leads to activation of the PI3K pathway. Understanding the signaling
    networks that drive drug resistance will enable the development of rational drug
    combinations to target melanomas refractory to BRAF inhibitors. Also shown are
    inhibitors that can be used to block the compensatory pathways identified so far.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - MAP2K1
  - MCL1
  - IGF1R
  - PIK3CG
  - PIK3R6
  - MAPK3
  - PDGFRB
  - PIK3R3
  - BRAF
  - MAPK1
  - RAF1
  - PIK3CD
  - ARAF
  - AKT2
  - CROT
  - PIK3CB
  - AKT3
  - AKT1
  - PTEN
  - NRAS
  - PIK3CA
  - HRAS
  - PIK3R4
  - PIK3R5
  - KRAS
  - GSK2141795
  - BMS-554417
  - AZD-6244
  - BEZ-235
  - GSK2126458
  - GSK2118436
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MCL-1
  symbol: Mcl-1
  source: hgnc_alias_symbol
  hgnc_symbol: MCL1
  entrez: '4170'
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: (ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PDGFR-B
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: (ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: ARAF
  symbol: ARAF
  source: hgnc_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: GSK2141795
  source: MESH
  identifier: C000595149
- word: BMS-554417
  source: MESH
  identifier: C507943
- word: AZD-6244
  source: MESH
  identifier: C517975
- word: BEZ-235
  source: MESH
  identifier: C531198
- word: GSK2126458
  source: MESH
  identifier: C561454
- word: GSK2118436
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
